PCSK9 inhibitors in neurodegenerative disorders: mechanisms, therapeutic potential, and clinical implications

Q: What is the clinical evidence from this study?

Study design: Review. Population: Neurodegenerative disorders and cardiovascular disease. Intervention: PCSK9 inhibitors (evolocumab, alirocumab, inclisiran) vs. Placebo or standard care. Primary outcome: Neurocognitive outcomes and neurodegenerative disease mechanisms.

Jia Dong James Wang; Andrea York Tiang Teo; Bin Xiao; Yinxia Chao; Zhi Dong Zhou; Brendan Jen‐Wei Tan; Ling-ling Chan; Elvira Rosalie; Eng‐King Tan

doi:10.1186/s40035-026-00568-y

August 18, 2026Translational NeurodegenerationOpen Access

PCSK9 inhibitors in neurodegenerative disorders: mechanisms, therapeutic potential, and clinical implications

View Full Paper

Ask AI

Bookmark

Share

Key result

PCSK9 inhibitors reduce MACE ~15% to 20% without causing adverse neurocognitive effects.

Why the study?

Do PCSK9 inhibitors affect neurocognitive outcomes or offer therapeutic potential in neurodegenerative disorders?

Key Points

To review the pathophysiological mechanisms, neurocognitive safety data, and therapeutic potential of PCSK9 inhibitors across neurodegenerative disorders such as Alzheimer's disease.
Narrative synthesis evaluating preclinical mechanistic models, human genetic datasets, and large-scale cardiovascular outcome trials.
Analysis of cognitive sub-studies from major trials, including CANTAB performance in 835 patients and APOE genotype-stratified outcomes in 13,481 FOURIER participants.
Large-scale randomized trials demonstrated that intensive LDL-C reduction with PCSK9 inhibitors causes no significant adverse effects on neuropsychological testing or patient-reported cognition.
In FOURIER, placebo recipients with APOE ε4/ε4 showed higher odds of reported memory decline (OR 1.46, 95% CI 1.03 to 2.08, P=0.003 for trend), which was not observed with evolocumab (OR 1.18, 95% CI 0.83 to 1.66, P=0.50; P=0.30 for interaction).
Genetic Mendelian randomization studies reported conflicting outcomes, with some showing increased Alzheimer's disease risk (OR ~1.45 per SD lower LDL-C) and others showing overall protective effects (OR ~0.64).

Structured PICO

Do PCSK9 inhibitors affect neurocognitive outcomes or offer therapeutic potential in neurodegenerative disorders?

P

Population

Patients with hypercholesterolemia, cardiovascular disease, or at risk for neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, and vascular dementia) evaluated across preclinical and clinical studies.

I

Intervention

PCSK9 inhibitors including monoclonal antibodies (evolocumab, alirocumab), siRNA therapies (inclisiran), and genetic knockdown/knockout strategies

C

Comparator

Placebo or standard lipid-lowering therapy in reviewed clinical trials

O

Outcome

Neuropsychological test performance (e.g., CANTAB, MoCA), patient-reported cognitive outcomes (ECog), clinically diagnosed neurocognitive adverse events, and preclinical neurodegenerative pathology (amyloid-beta clearance, neuroinflammation, synaptic plasticity)safety

Limitations

Direct CNS target engagement by systemically administered PCSK9 inhibitors remains unproven due to limited blood-brain barrier penetration.
Current clinical datasets lack the statistical power and follow-up duration to detect rare or subtle outcomes like progression to mild cognitive impairment or Alzheimer's disease.
No clinical trials have specifically tested PCSK9 inhibitors on the progression of established Alzheimer's disease or vascular dementia.
No studies have directly examined the effects of PCSK9 on alpha-synuclein in cellular or animal models of Parkinson's disease.
Direct CNS target engagement by current systemically administered PCSK9 inhibitors remains unproven due to large molecular size and limited blood-brain barrier penetration.
Current clinical trial datasets lack statistical power to detect rare or subtle long-term outcomes such as progression to mild cognitive impairment or Alzheimer's dementia.
No clinical trials to date have specifically evaluated PCSK9 inhibitors in patients with established Alzheimer's disease or vascular dementia.
Conflicting evidence exists between preclinical models, human CSF studies, and Mendelian randomization analyses regarding Alzheimer's disease risk.
No experimental studies have directly examined the effects of PCSK9 on alpha-synuclein pathology in cellular or animal models of Parkinson's disease.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

This comprehensive review confirms the long-term neurocognitive safety of intensive LDL-C lowering with PCSK9 inhibitors and highlights emerging preclinical mechanisms by which PCSK9 modulation may protect against neurodegeneration.

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a role in hepatic cholesterol metabolism via low density lipoprotein receptor degradation. PCSK9 inhibitors have revolutionized lipid-lowering therapy, providing robust reduction of cardiovascular risk. Large-scale randomized controlled trials and long-term extensions (e.g., FOURIER and EBBINGHAUS trials) have shown no significant adverse effects of PCSK9 inhibitors on neuropsychological testing or patient-reported cognitive outcomes, even with prolonged and intensive lowering of low-density lipoproteins. Pre-clinical studies also suggest PCSK9 as a key regulator of neurobiological processes, including synaptic plasticity, amyloid-beta clearance, neuroinflammation, and blood–brain barrier integrity. Human genetic studies revealed complex, sometimes conflicting associations between PCSK9 variants and risk of Alzheimer’s disease, Parkinson’s disease, vascular dementia, and amyotrophic lateral sclerosis. In this review, we highlight the pathophysiologic mechanisms, emerging experimental therapeutics and clinical implications of PCSK9 inhibition in neurodegenerative disorders. Long-term adequately powered trials with robust neuropsychological, biomarker, and imaging endpoints, as well as mechanistic studies in human-derived models are needed to establish the cardiovascular and neurocognitive implications of PCSK9 inhibition and guide precision medicine strategies for those at elevated risk of neurodegeneration.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2026) conducted a review in Neurodegenerative disorders and cardiovascular disease. PCSK9 inhibitors (evolocumab, alirocumab, inclisiran) vs. Placebo or standard care was evaluated on Neurocognitive outcomes and neurodegenerative disease mechanisms. PCSK9 inhibitors achieve 50%–60% LDL-C reductions and 15%–20% MACE reductions without causing adverse neurocognitive effects in clinical trials, while showing neuroprotective mechanisms preclinically.

synapsesocial.com/papers/6a86b6208a91293e6a1cdb88 https://doi.org/10.1186/s40035-026-00568-y

View Full Paper

Ask AI

Bookmark

Share

PCSK9 inhibitors in neurodegenerative disorders: mechanisms, therapeutic potential, and clinical implications

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

PCSK9 inhibitors in neurodegenerative disorders: mechanisms, therapeutic potential, and clinical implications

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading